Since only a fraction of HER2+ breast cancer patients are responsive to the combination of anti-HER2 therapies and immune checkpoint inhibitors, a more comprehensive recognition of the composition of immune infiltration in the tumor microenvironment seems to be helpful in predicting treatment response and optimizing treatment strategy. This evidence concerns the gene ERBB2 and breast carcinoma.